The serotonin theory of depression: a systematic review of the evidence (2022)
Evidence casting doubt on the “low serotonin” explanation of depression has prompted renewed scrutiny of how SSRIs work and how effective they really are. Commenters note that while these drugs show only modest advantages over placebo in trials and often have significant side effects, some patients experience life-changing benefits, complicating simple narratives that they are either useless or miraculous. Many argue for a broader view of depression that includes sociological factors, therapy, lifestyle changes, and alternative treatments, while acknowledging the limits of current science in explaining or predicting who will benefit from which intervention.
Serotonin theory vs. SSRIs
- Commenters distinguish the “serotonin theory/hypothesis of depression” from the clinical question of whether SSRIs help.
- Many note the field has long known that “low serotonin causes depression” is oversimplified and not well supported by evidence, even as SSRIs can still be useful drugs.
- Some argue over semantics of “theory” vs “hypothesis” but others see this as a distraction from the substantive issues.
How SSRIs work (and what we don’t know)
- Repeated emphasis that neurotransmitters are not simple “levels”; SSRIs change timing, receptor sensitivity (e.g., 5‑HT1A autoreceptor downregulation), and network dynamics over weeks.
- Several note the delayed clinical effect despite rapid serotonin changes, arguing this alone disproves the “nutritional deficit” story.
- Broader point: neuropsychopharmacology is extremely complex (many receptor subtypes, neuromodulation, cross‑talk between systems), so naive “happy chemical” narratives are misleading but popular (including in drug advertising).
Efficacy, placebo, and measurement problems
- Strong disagreement about how well SSRIs work.
- One camp stresses small average effect sizes and marginal advantage over placebo, especially in better‑blinded or active‑placebo trials, plus publication bias.
- Another camp counters that:
- Placebo itself performs unusually well in depression.
- Some patients show large benefits even if averages are small.
- Effect sizes for SSRIs are in the same ballpark as widely used drugs like morphine for pain.
- Challenges highlighted: subjective outcome measures, strong expectancy/placebo effects, lack of “no‑treatment” controls, and heterogeneity of “depression” as a category.
Side effects, withdrawal, and overuse
- Sexual dysfunction (sometimes persistent), emotional blunting, and possible weight gain are major concerns; some report life‑altering harms, others report manageable or transient issues.
- Withdrawal can be severe; slow tapering is strongly recommended.
- Many think SSRIs are over‑prescribed and often used as first‑line tools because they’re cheap and scalable, while therapy and other supports are less accessible.
Alternatives, complements, and broader framings
- Multiple comments advocate combining SSRIs with psychotherapy, or prioritizing exercise, sleep, sunlight, weight loss, social and “meaning” interventions, and addressing trauma or social context.
- Other pharmacologic options mentioned: bupropion, stimulants, MAOIs/tricyclics, ketamine, TMS/ECT, GLP‑1 agonists.
- There are anecdotal reports of benefit from 5‑HTP and other supplements, alongside cautions about serotonin syndrome and self‑experimentation.
- Several stress sociological and life‑context understandings of depression as more helpful than purely biological models.